ACV meeting #31, 8 February 2022

The meeting of the Advisory Committee on Vaccines (ACV).

The committee provided advice on the:

• extension of indication for a vaccine with provisional registration for active immunisation to prevent COVID-19 (product name Spikevax; active ingredient Elasomeran; sponsor Moderna Australia Pty Ltd) that had been under evaluation from November 2021.

The committee provided advice on the following safety matter.

• Risk of Haemophagocytic lymphohistiocytosis (HLH) associated with Vaxzevria (formerly known as COVID-19 vaccine AstraZeneca)

Members

Membership comprises professionals with expertise in specific scientific, medical or clinical fields, or consumer health issues.